Viemed Healthcare, Inc. · NASDAQ:VMD
Viemed Healthcare — Q3 2025 Earnings Presentation
10 slides from Viemed Healthcare's earnings presentation, Nov 5, 2025
Slide 1: Financial Supplement Third Quarter 2025
Financial Supplement NASDAQ: VMD Leading th e Healthcare Industry in Home Respiratory Care November 5, 2025 1 Third Quarter 2025
Slide 2: Disclaimers: Forward Looking Statements
Disclaimers Forward Looking Statements Certain statements contained in this Financial Supplement may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian
Slide 3: Key Themes for Q3 2025
Key Themes for Q3 2025 3 Delivered record third-quarter results marked by strong execution and sustained expansion of our patient base across major service lines. Completed all repurchases authorized under the 2025 share repurchase program, repurchasing $11.4 million worth of common shares during th
Slide 4: Financial and Operational Highlights
Financial and Operational Highlights 4 (expressed in thousands of U.S. Dollars, except operational information). (1) Refer to "Non-GAAP Reconciliations" in this presentation for definition of Adjusted EBITDA and a reconciliation to its most comparable GAAP measure. (2) Vent Patients represents the n
Slide 5: Service, Payor and Revenue Mix
Medicare 37% Medicaid/ MCO 8% Medicare Advantage 20% Commercial 23% Other 12% Ventilation 49% Sleep 21% Oxygen 9% Staffing 8% Other 7% Maternal 6% Q3 2025 Rental 70% Sales 30% Medicare 40% Medicaid/ MCO 7% Medicare Advantage 22% Commercial 19% Other 12% Ventilation 55% Sleep 17% Oxygen 11% Staffing
Slide 6: Revenue Highlights
Revenue Highlights 6 For the quarter ended 9/30/25 6/30/25 3/31/25 12/31/24 9/30/24 6/30/24 3/31/24 12/31/23 Rental Revenue (expressed in thousands of USD): Ventilators, non-invasive & invasive $34,883 $33,819 $32,159 $33,173 $31,772 $30,445 $29,187 $29,077 Other home medical equipment rentals $15,4
Slide 7: Liquidity Metrics
Liquidity Metrics 7 Positioned for growth • The Company maintains a healthy balance sheet with only $10 million of net debt as of September 30, 2025, providing significant financial flexibility. • As of September 30, 2025, the Company had $38 million in unfunded commitments available under its exist
Slide 8: Free Cash Flow
Free Cash Flow 8 TTM For the quarter ended 9/30/25 9/30/25 6/30/25 3/31/25 12/31/24 Net cash provided by operating activities $ 48,462 $ 18,367 $ 12,254 $ 2,854 $ 14,987 Less: Purchase of property and equipment (43,077) (7,636) (8,129) (15,483) (11,829) Proceeds from sale of property and equipment 1
Slide 9: 2025 Guidance – Commentary
2025 Guidance – Commentary 9 Core Metrics • Net revenue of $271 million to $273 million, from $271 million to $277 million • Adjusted EBITDA of $60 million to $62 million (≈22% of net revenue), from $59 million to $62 million Commentary on Guidance • Lower-margin services, including staffing, now ex
Slide 10: Adjusted EBITDA
Adjusted EBITDA 10 (a) Represents non-cash, equity-based compensation expense associated with option and RSU awards. (b) Represents transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions. (c) Represents impairments o